menu search

Alpine immune sciences: november 2023 data release could get ball rolling

Preliminary clinical data from the Alpine Immune Sciences, Inc. ongoing phase 3 RUBY-3 study will be presented at the American Society of Nephrology A...

October 6, 2023, 3:31 pm

In a push to limit use of glucocorticoids, us and eu5 rheumatologists are increasingly turning to gsk’s benlysta and astrazeneca’s saphnelo for the treatment of moderate-to-severe systemic lupus eryth

Despite overall biologic growth in both geographies, use of advanced systemic treatments in the US outpaces the EU5. Exton, Pennsylvania, Oct. 04, 202...

October 4, 2023, 7:00 am

Horizon's (hznp) daxdilimab fails to meet goal in lupus study

Horizon (HZNP) fails to meet the primary endpoint in the mid-stage study of evaluating daxdilimab in the treatment of systemic lupus erythematosus....

July 24, 2023, 12:20 pm

Immupharma presses on with next phase of lupuzor clinical trials

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) is set to initiate a Phase 2/3 adaptive clinical trial for its P140 (Lupuzor) drug in systemic lupus ...

June 19, 2023, 4:11 am

Immupharma partner gets fda meeting date

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) has confirmed a Type-C meeting is scheduled with the US Food & Drug Administration for June 7. Scientists will di...

April 19, 2023, 2:28 am

Immupharma: us partner has submitted lupuzor phase ii/iii trial protocol

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) has said its partner Avion Pharmaceuticals has submitted the phase II/III clinical protocol for Lupuzor to the Fo...

March 27, 2023, 2:51 am

Abbvie (abbv) provides clinical updates on inflammatory drugs

AbbVie???s (ABBV) two studies evaluating Skyrizi in ulcerative colitis and Rinvoq in systemic lupus erythemato...

March 24, 2023, 2:28 pm

Why is nektar therapeutics (nktr) stock down 39% today?

Nektar Therapeutics (NASDAQ: NKTR ) stock is taking a beating on Friday following the release of Phase 2 clinical trial data. This Phase 2 study had N...

February 24, 2023, 8:56 am

Immupharma partner agrees phase ii/iii clinical trial process

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) said partner Avion Pharmaceuticals is to launch an adaptive phase II/III clinical study on Lupuzor, the former's d...

February 6, 2023, 2:18 am

Astrazeneca's (azn) lupus drug saphnelo gets europe nod

AstraZeneca's (AZN) Saphnelo is the only new biologic to be approved in Europe in over a decade for patients with systemic lupus erythematosus....

February 17, 2022, 12:19 pm

Astrazeneca's (azn) lupus drug saphnelo gets europe nod

AstraZeneca's (AZN) Saphnelo is the only new biologic to be approved in Europe in over a decade for patients with systemic lupus erythematosus....

February 17, 2022, 12:19 pm

Astrazeneca's (azn) lupus drug saphnelo gets europe nod

AstraZeneca's (AZN) Saphnelo is the only new biologic to be approved in Europe in over a decade for patients with systemic lupus erythematosus....

February 17, 2022, 12:19 pm

Astrazeneca eu wins approval for the first drug in more than a decade for lupus

AstraZeneca PLC (LSE:AZN) has received EU approval for the first new drug in over a decade for people with systemic lupus ...

February 16, 2022, 2:33 am

Astrazeneca eu wins approval for the first drug in more than a decade for lupus

AstraZeneca PLC (LSE:AZN) has received EU approval for the first new drug in over a decade for people with systemic lupus ...

February 16, 2022, 2:33 am

Astrazeneca eu wins approval for the first drug in more than a decade for lupus

AstraZeneca PLC (LSE:AZN) has received EU approval for the first new drug in over a decade for people with systemic lupus ...

February 16, 2022, 2:33 am


Search within

Pages Search Results: